XCUR Exicure Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XCUR

Price (delayed)

$0.501

Market cap

$4.33M

P/E Ratio

0.3

Dividend/share

N/A

EPS

$1.68

Enterprise value

$8.42M

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes its proprietary ...

Highlights
Exicure's EPS has soared by 140% from the previous quarter and by 110% YoY
The net income has soared by 126% since the previous quarter and by 106% year-on-year
The quick ratio has plunged by 55% from the previous quarter but it has grown by 44% YoY
XCUR's equity is down by 34% since the previous quarter
XCUR's revenue is down by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exicuretx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of XCUR
Market
Shares outstanding
8.65M
Market cap
$4.33M
Enterprise value
$8.42M
Valuations
Price to earnings (P/E)
0.3
Price to book (P/B)
0.43
Price to sales (P/S)
0.18
EV/EBIT
2.57
EV/EBITDA
1.67
EV/Sales
0.35
Earnings
Revenue
$23.79M
EBIT
$3.27M
EBITDA
$5.04M
Free cash flow
-$21.54M
Per share
EPS
$1.68
Free cash flow per share
-$2.55
Book value per share
$1.16
Revenue per share
$2.82
TBVPS
$2.08
Balance sheet
Total assets
$17.56M
Total liabilities
$7.85M
Debt
$6.42M
Equity
$9.71M
Working capital
$2.23M
Liquidity
Debt to equity
0.66
Current ratio
2.56
Quick ratio
1.63
Net debt/EBITDA
0.81
Margins
EBITDA margin
21.2%
Gross margin
100%
Net margin
12.9%
Operating margin
13.5%
Efficiency
Return on assets
13.1%
Return on equity
34.5%
Return on invested capital
25%
Return on capital employed
20.3%
Return on sales
13.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XCUR stock price

How has the Exicure stock price performed over time
Intraday
0.2%
1 week
0.2%
1 month
-10.54%
1 year
-53.61%
YTD
-13.67%
QTD
-16.71%

Financial performance

How have Exicure's revenue and profit performed over time
Revenue
$23.79M
Gross profit
$23.79M
Operating income
$3.21M
Net income
$3.07M
Gross margin
100%
Net margin
12.9%
Exicure's operating margin has surged by 160% QoQ and by 101% YoY
The net margin has soared by 148% from the previous quarter and by 101% YoY
XCUR's operating income has surged by 135% since the previous quarter and by 106% year-on-year
The net income has soared by 126% since the previous quarter and by 106% year-on-year

Growth

What is Exicure's growth rate over time

Valuation

What is Exicure stock price valuation
P/E
0.3
P/B
0.43
P/S
0.18
EV/EBIT
2.57
EV/EBITDA
1.67
EV/Sales
0.35
Exicure's EPS has soared by 140% from the previous quarter and by 110% YoY
XCUR's P/B is 88% below its 5-year quarterly average of 3.7
XCUR's equity is down by 34% since the previous quarter
The stock's price to sales (P/S) is 55% less than its last 4 quarters average of 0.4
XCUR's revenue is down by 9% since the previous quarter

Efficiency

How efficient is Exicure business performance
The ROA has soared by 173% from the previous quarter and by 114% YoY
Exicure's ROS has soared by 130% from the previous quarter and by 101% YoY
Exicure's ROIC has soared by 106% YoY and by 41% from the previous quarter
XCUR's ROE has soared by 105% YoY and by 72% QoQ

Dividends

What is XCUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XCUR.

Financial health

How did Exicure financials performed over time
The company's total assets is 124% higher than its total liabilities
Exicure's current ratio has soared by 103% YoY but it has decreased by 38% from the previous quarter
Exicure's total liabilities has shrunk by 78% YoY and by 16% QoQ
The debt is 34% less than the equity
Exicure's debt to equity has shrunk by 89% YoY but it has increased by 47% QoQ
XCUR's equity is down by 34% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.